Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene - PubMed (original) (raw)

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

D J Slamon et al. Science. 1987.

Abstract

The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.

PubMed Disclaimer

Similar articles

• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
  Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D. Andrulis IL, et al. J Clin Oncol. 1998 Apr;16(4):1340-9. doi: 10.1200/JCO.1998.16.4.1340. J Clin Oncol. 1998. PMID: 9552035
• The association of HER-2/neu amplification with breast cancer recurrence.
  Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V. Carr JA, et al. Arch Surg. 2000 Dec;135(12):1469-74. doi: 10.1001/archsurg.135.12.1469. Arch Surg. 2000. PMID: 11115354
• HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
  Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. Tiwari RK, et al. Anticancer Res. 1992 Mar-Apr;12(2):419-25. Anticancer Res. 1992. PMID: 1349794
• Follow-up study of HER-2/neu amplification in primary breast cancer.
  Clark GM, McGuire WL. Clark GM, et al. Cancer Res. 1991 Feb 1;51(3):944-8. Cancer Res. 1991. PMID: 1988136 Review.
• The significance of oncogene amplification in primary breast cancer.
  Seshadri R, Matthews C, Dobrovic A, Horsfall DJ. Seshadri R, et al. Int J Cancer. 1989 Feb 15;43(2):270-2. doi: 10.1002/ijc.2910430218. Int J Cancer. 1989. PMID: 2563720 Review.

Cited by

• Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021.
  Zhao H, Shen C, Laureano JJ, Lei X, Niu J, Giordano SH, Chavez-MacGregor M. Zhao H, et al. Breast Cancer Res Treat. 2024 Nov 22. doi: 10.1007/s10549-024-07552-y. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39576449
• DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2+ breast cancer.
  Yan J, Xie Y, Liu Z, Yang Y, Zhou T. Yan J, et al. J Immunother Cancer. 2024 Nov 14;12(11):e009636. doi: 10.1136/jitc-2024-009636. J Immunother Cancer. 2024. PMID: 39542653 Free PMC article.
• Updates in Treatment of HER2-positive Metastatic Breast Cancer.
  Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Avelino ARM, et al. Curr Treat Options Oncol. 2024 Dec;25(12):1471-1481. doi: 10.1007/s11864-024-01277-2. Epub 2024 Nov 9. Curr Treat Options Oncol. 2024. PMID: 39520520 Review.
• Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan.
  Nusawat C, Sato S, Watanabe H, Konishi T, Yamana H, Yasunaga H. Nusawat C, et al. Clin Drug Investig. 2024 Dec;44(12):927-938. doi: 10.1007/s40261-024-01399-3. Epub 2024 Nov 7. Clin Drug Investig. 2024. PMID: 39511130 Free PMC article.
• Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study.
  Huang A, Zhao Y, Guan F, Zhang H, Luo B, Xie T, Chen S, Chen X, Ai S, Ju X, Yan H, Yang L, Yuan J. Huang A, et al. Comput Struct Biotechnol J. 2024 Oct 5;26:40-50. doi: 10.1016/j.csbj.2024.10.007. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 39469445 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal